Praxis precision medicines announces management team appointments

Boston, dec. 02, 2021 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal imbalance, today announced the appointment of megan sniecinski as chief business officer and provided key updates on members of the executive leadership team. praxis has promoted alyssa wyant to chief regulatory and quality officer and karl hansen, ph.d., to chief technical operations officer. in addition, chief scientific officer and co-founder, steven petrou, ph.d., has decided to fully dedicate his time to praxis upon stepping down from his role as institute director of the florey institute of neuroscience and mental health.
PRAX Ratings Summary
PRAX Quant Ranking